Stay updated on Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial
Sign up to get notified when there's something new on the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page.

Latest updates to the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page
- CheckyesterdayChange DetectedAdded Revision: v3.3.4 and removed Prostate cancer, MedlinePlus Genetics, and the related topics header, along with Revision: v3.3.3.SummaryDifference0.2%

- Check8 days agoChange DetectedAdded related topics: Prostate cancer and MedlinePlus Genetics.SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedLocations section updated to include New York and Wisconsin as study sites. Location subsections were reorganized under a new Locations header.SummaryDifference0.3%

- Check44 days agoChange DetectedThe page now shows Revision: v3.3.2 instead of v3.3.1; there are no visible changes to the study details or layout.SummaryDifference0.1%

- Check52 days agoChange DetectedFooter revision label updated from v3.2.0 to v3.3.1. The change does not modify study details, eligibility criteria, or results information.SummaryDifference0.1%

- Check59 days agoChange DetectedRemoved a general government funding/operating status notice from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page.